IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-02-14 |
2023-12 |
0 |
-0.09 |
N/A |
N/A |
2023-11-09 |
2023-09 |
0 |
-0.05 |
N/A |
N/A |
2023-08-10 |
2023-06 |
0 |
-0.04 |
N/A |
N/A |
2023-07-07 |
2023-03 |
0 |
-0.08 |
N/A |
N/A |
2023-02-14 |
2022-12 |
0 |
-0.04 |
N/A |
N/A |
2022-11-01 |
2022-09 |
0 |
-0.05 |
N/A |
N/A |
Date |
Name |
Relation |
Quantity |
Description |
2017-02-23 |
CHERIN JOHN |
Chief Financial Officer |
373.95K |
Stock Award(Grant) |
2021-05-12 |
GOEL ROHIT |
Officer |
235.00K |
Stock Award(Grant) |
2024-03-12 |
GRIMALDI CLAUDIA |
Director |
1.04M |
Conversion of Exercise of derivative security |
2012-08-06 |
KRISHNA RANGA C |
Director |
1.07M |
Purchase |
2022-05-31 |
LYNCH JOHN EDWARD |
Director |
134.40K |
Conversion of Exercise of derivative security |
2024-03-12 |
MORAN JAMES P |
Director |
354.17K |
Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
755.79K |
235.50K |
1.91% |
2023-06-29 |
Vanguard Group Inc |
646.54K |
201.46K |
1.63% |
2023-06-29 |
Geode Capital Management, LLC |
302.14K |
94.15K |
0.76% |
2023-06-29 |
State Street Corporation |
184.11K |
57.37K |
0.47% |
2023-06-29 |
Renaissance Technologies, LLC |
162.71K |
50.70K |
0.41% |
2023-06-29 |
Dearborn Partners, L.L.C. |
116.71K |
36.37K |
0.29% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Extended Market Index Fund |
630.22K |
196.38K |
1.59% |
2023-05-30 |
Fidelity Extended Market Index Fund |
176.10K |
51.07K |
0.44% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
69.00K |
21.50K |
0.17% |
2023-05-30 |
Fidelity Total Market Index Fund |
57.86K |
16.78K |
0.15% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
42.33K |
12.28K |
0.11% |
2023-08-30 |
iShares Core S&P Total U.S. Stock Market ETF |
38.05K |
13.16K |
0.10% |
Split |
Date |
0.1 : 1 |
2013-04-19 |